AFT Pharmaceuticals enters iron medicine partnership, sees global growth

AFT Pharmaceuticals (NZX:AFT) has announced a partnership with Belgium's Hyloris Pharmaceuticals to advance a novel injectable iron therapy to Phase 3 trials, targeting a US$7.4 billion global market. The agreement adds to AFT's existing R&D pipeline of 13 projects. The company also highlighted its successful Crystaderm launch in China, contributing to AFT accounting for two of the 19 in-licensing deals in that market in 2024. AFT expects record sales of over $200 million (excluding license income) in FY25 and remains focused on achieving a $300 million turnover by FY27. With operations in multiple countries and distribution agreements covering over 100 markets, AFT sees significant opportunities to extend its global footprint.